Literature DB >> 27213184

Novel mechanisms of regulation of miRNAs in CLL.

Veronica Balatti1, Mario Acunzo1, Yuri Pekarky1, Carlo M Croce1.   

Abstract

B-cell chronic lymphocytic leukemia (CLL) is the most common adult human leukemia. Although, the molecular alterations leading to CLL onset and progression are still under investigation (specifically, the interplay and exact role of oncogenes and tumor suppressors in CLL pathogenesis). MicroRNAs are small non-coding RNAs that regulate gene expression and are expressed in a tissue specific manner. Deregulation of microRNAs can alter expression levels of genes involved in the development and/or progression of tumors. In CLL, microRNAs can function as oncogenes or tumor suppressors. Here, we review the most recent findings on the role of microRNAs in the onset/progression of CLL, and how this knowledge can be used to identify new biomarkers and targets to treat this leukemia.

Entities:  

Keywords:  CLL; miR-15/16; microRNA

Year:  2016        PMID: 27213184      PMCID: PMC4874335          DOI: 10.1016/j.trecan.2016.02.005

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  71 in total

1.  MicroRNAs regulate B-cell receptor signaling-induced apoptosis.

Authors:  J L Kluiver; C-Z Chen
Journal:  Genes Immun       Date:  2012-02-23       Impact factor: 2.676

2.  Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL).

Authors:  Alexey Palamarchuk; Pearlly S Yan; Nicola Zanesi; Linan Wang; Benjamin Rodrigues; Mark Murphy; Veronica Balatti; Arianna Bottoni; Natalya Nazaryan; Hansjuerg Alder; Laura Rassenti; Thomas J Kipps; Michael Freitas; Carlo M Croce; Yuri Pekarsky
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

3.  Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling.

Authors:  Yuh-Ying Yeh; Hatice Gulcin Ozer; Amy M Lehman; Kami Maddocks; Lianbo Yu; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

4.  Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia.

Authors:  Alessandra Ferrajoli; Tait D Shanafelt; Cristina Ivan; Masayoshi Shimizu; Kari G Rabe; Nazila Nouraee; Mariko Ikuo; Asish K Ghosh; Susan Lerner; Laura Z Rassenti; Lianchun Xiao; Jianhua Hu; James M Reuben; Steliana Calin; M James You; John T Manning; William G Wierda; Zeev Estrov; Susan O'Brien; Thomas J Kipps; Michael J Keating; Neil E Kay; George A Calin
Journal:  Blood       Date:  2013-07-02       Impact factor: 22.113

5.  17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation.

Authors:  M K Dijkstra; K van Lom; D Tielemans; F Elstrodt; A W Langerak; M B van 't Veer; M Jongen-Lavrencic
Journal:  Leukemia       Date:  2008-09-25       Impact factor: 11.528

6.  Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice.

Authors:  Elizabeth S Raveche; Erica Salerno; Brian J Scaglione; Vijaya Manohar; Fatima Abbasi; Yi-Chu Lin; Torgny Fredrickson; Pablo Landgraf; Sumant Ramachandra; Konrad Huppi; Jorge R Toro; Vincent E Zenger; Robert A Metcalf; Gerald E Marti
Journal:  Blood       Date:  2007-03-09       Impact factor: 22.113

7.  The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.

Authors:  Ulf Klein; Marie Lia; Marta Crespo; Rachael Siegel; Qiong Shen; Tongwei Mo; Alberto Ambesi-Impiombato; Andrea Califano; Anna Migliazza; Govind Bhagat; Riccardo Dalla-Favera
Journal:  Cancer Cell       Date:  2010-01-07       Impact factor: 31.743

8.  Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest.

Authors:  Valery Tarasov; Peter Jung; Berlinda Verdoodt; Dmitri Lodygin; Alexey Epanchintsev; Antje Menssen; Gunter Meister; Heiko Hermeking
Journal:  Cell Cycle       Date:  2007-05-11       Impact factor: 4.534

9.  Is miR-29 an oncogene or tumor suppressor in CLL?

Authors:  Yuri Pekarsky; Carlo M Croce
Journal:  Oncotarget       Date:  2010-07

10.  microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells.

Authors:  Elena Vigorito; Kerry L Perks; Cei Abreu-Goodger; Sam Bunting; Zou Xiang; Susan Kohlhaas; Partha P Das; Eric A Miska; Antony Rodriguez; Allan Bradley; Kenneth G C Smith; Cristina Rada; Anton J Enright; Kai-Michael Toellner; Ian C M Maclennan; Martin Turner
Journal:  Immunity       Date:  2007-12-06       Impact factor: 31.745

View more
  9 in total

1.  Targeting BTK through microRNA in chronic lymphocytic leukemia.

Authors:  Arianna Bottoni; Lara Rizzotto; Tzung-Huei Lai; Chaomei Liu; Lisa L Smith; Rose Mantel; Sean Reiff; Dalia El-Gamal; Karilyn Larkin; Amy J Johnson; Rosa Lapalombella; Amy Lehman; William Plunkett; John C Byrd; James S Blachly; Jennifer A Woyach; Deepa Sampath
Journal:  Blood       Date:  2016-10-17       Impact factor: 22.113

Review 2.  Dysregulation of miRNA in Leukemia: Exploiting miRNA Expression Profiles as Biomarkers.

Authors:  Luisa Anelli; Antonella Zagaria; Giorgina Specchia; Pellegrino Musto; Francesco Albano
Journal:  Int J Mol Sci       Date:  2021-07-02       Impact factor: 5.923

3.  MicroRNA-181 as a prognostic biomarker for survival in acute myeloid leukemia: a meta-analysis.

Authors:  Qiang Guo; Junwen Luan; Ni Li; Zhen Zhang; Xiaoxiao Zhu; Lin Zhao; Ran Wei; Linlin Sun; Yin Shi; Xunqiang Yin; Na Ding; Guosheng Jiang; Xia Li
Journal:  Oncotarget       Date:  2017-07-12

4.  RNA Editing Alters miRNA Function in Chronic Lymphocytic Leukemia.

Authors:  Franz J Gassner; Nadja Zaborsky; Daniel Feldbacher; Richard Greil; Roland Geisberger
Journal:  Cancers (Basel)       Date:  2020-05-05       Impact factor: 6.639

5.  Interpreting the MicroRNA-15/107 family: interaction identification by combining network based and experiment supported approach.

Authors:  Si Wang; Wenhua Zhu; Jing Xu; Yuanxu Guo; Jidong Yan; Liesu Meng; Congshan Jiang; Shemin Lu
Journal:  BMC Med Genet       Date:  2019-05-31       Impact factor: 2.103

6.  RNA-Seq profiling of deregulated miRs in CLL and their impact on clinical outcome.

Authors:  Gurvinder Kaur; Vivek Ruhela; Lata Rani; Anubha Gupta; Krishnamachari Sriram; Ajay Gogia; Atul Sharma; Lalit Kumar; Ritu Gupta
Journal:  Blood Cancer J       Date:  2020-01-13       Impact factor: 11.037

7.  BTLA Expression in CLL: Epigenetic Regulation and Impact on CLL B Cell Proliferation and Ability to IL-4 Production.

Authors:  Lidia Karabon; Anna Andrzejczak; Lidia Ciszak; Anna Tomkiewicz; Aleksandra Szteblich; Agnieszka Bojarska-Junak; Jacek Roliński; Dariusz Wołowiec; Tomasz Wróbel; Agata Kosmaczewska
Journal:  Cells       Date:  2021-11-04       Impact factor: 6.600

8.  Physiological Fitness and the Pathophysiology of Chronic Lymphocytic Leukemia (CLL).

Authors:  Andrea Sitlinger; Michael A Deal; Erwin Garcia; Dana K Thompson; Tiffany Stewart; Grace A MacDonald; Nicolas Devos; David Corcoran; Janet S Staats; Jennifer Enzor; Kent J Weinhold; Danielle M Brander; J Brice Weinberg; David B Bartlett
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

Review 9.  Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia.

Authors:  Felice Pepe; Veronica Balatti
Journal:  J Clin Med       Date:  2020-02-21       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.